SCHEMBL4213620

SCHEMBL4213620

O=c1c2c(Cl)cc(Cl)cc2n(Cc2ccccc2)c(=O)n1Cc1ccc(I)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.50
TSHR P16473 2/20 0.49
KDM4E B2RXH2 1/20 0.49
KDM4A O75164 1/20 0.49
ALDH1A1 P00352 1/20 0.49
HPGD P15428 1/20 0.49
HTT P42858 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
HSD17B10 Q99714 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
MAPK8 P45983 2/20 0.46
MAPK9 P45984 2/20 0.46
PDE7A Q13946 1/20 0.44
TP53 P04637 2/20 0.43
HDAC6 Q9UBN7 4/20 0.42
HDAC1 Q13547 3/20 0.41
HDAC8 Q9BY41 2/20 0.41
C5AR1 P21730 1/20 0.41
HDAC11 Q96DB2 1/20 0.41
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4227625 0.92 MAPT (0.57) MAPTTSHRKDM4EKDM4AALDH1A1
SCHEMBL4214380 0.91 MAPT (0.53) MAPTTSHRKDM4EKDM4AALDH1A1
SCHEMBL4213415 0.90 MAPT (0.54) MAPTTSHRKDM4EKDM4AALDH1A1
SCHEMBL4217708 0.87 MAPT (0.50) MAPTTSHRKDM4EKDM4AALDH1A1
SCHEMBL4214307 0.87 TP53 (0.54) MAPTTSHRKDM4EKDM4AALDH1A1
SCHEMBL4217821 0.87 MAPT (0.50) MAPTTSHRKDM4EKDM4AALDH1A1
SCHEMBL4223829 0.86 MAPT (0.50) MAPTTSHRKDM4EKDM4AALDH1A1
SCHEMBL4226156 0.86 MAPT (0.68) MAPTTSHRKDM4EKDM4AALDH1A1
SCHEMBL4220996 0.85 MAPT (0.57) MAPTTSHRKDM4EKDM4AALDH1A1
SCHEMBL4216078 0.85 KDM4E (0.52) MAPTTSHRKDM4EKDM4AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090203708-A1 NOVEL SUBSTITUTED-1-H-QUINAZOLINE-2,4-DIONE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2009-08-13 US disclosed
US-20090203708-A1 NOVEL SUBSTITUTED-1-H-QUINAZOLINE-2,4-DIONE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2009-08-13 US disclosed
US-20090203708-A1 NOVEL SUBSTITUTED-1-H-QUINAZOLINE-2,4-DIONE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2009-08-13 US disclosed
EP-2035406-A4 NOVEL SUBSTITUTED-1H-QUINAZOLINE-2,4-DIONE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RES INST CHEM TECH (KR) 2009-08-05 EP disclosed
EP-2035406-A1 NOVEL SUBSTITUTED-1H-QUINAZOLINE-2,4-DIONE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME Korea Research Institute of Chemical Technology (KR) 2009-03-18 EP disclosed
WO-2008004716-A1 NOVEL SUBSTITUTED-1H-QUINAZOLINE-2,4-DIONE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME KOREA RESERACH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2008-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203708-A1 NOVEL SUBSTITUTED-1-H-QUINAZOLINE-2,4-DIONE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME HTR5A, HTR3B, HTR1A MAPT 2568/4885TSHR 443/4885KDM4E 3808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.